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Proteomic proﬁles of myocardial tissue in two diﬀerent etiologies of heart failure were investigated using high performance liquid
chromatography (HPLC)/Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS). Right atrial appendages
from 10 patients with hemodynamically signiﬁcant isolated aortic valve disease and from 10 patients with isolated symptomatic
coronary heart disease were collected during elective cardiac surgery. As presented in an earlier study by our group (Baykut
et al., 2006), both disease forms showed clearly diﬀerent pattern distribution characteristics. Interesting enough, the classiﬁcation
patterns could be used for correctly sorting unknown test samples in their correct categories. However, in order to fully exploit and
also validate these ﬁndings there is a deﬁnite need for unambiguous identiﬁcation of the diﬀerences between diﬀerent etiologies
at molecular level. In this study, samples representative for the aortic valve disease and coronary heart disease were prepared,
tryptically digested, and analyzed using an FT-ICR MS that allowed collision-induced dissociation (CID) of selected classiﬁer
masses. By using the fragment spectra, proteins were identiﬁed by database searches. For comparison and further validation,
classiﬁer masses were also fragmented and analyzed using HPLC-/Matrix-assisted laser desorption ionization (MALDI) time-of-
ﬂight/time-of-ﬂight (TOF/TOF) mass spectrometry. Desmin and lumican precursor were examples of proteins found in aortic
samples at higher abundances than in coronary samples. Similarly, adenylate kinase isoenzyme was found in coronary samples at
a higher abundance. The described methodology could also be feasible in search for speciﬁc biomarkers in plasma or serum for
diagnostic purposes.
1.Introduction
Understanding the diﬀerences of proteomic proﬁles has
a crucial importance for gaining insight into molecular
mechanisms of disease. Although the molecular origin of the
cardiac dysfunction is still largely unknown in the majority
of heart diseases [1, 2], heart insuﬃciency is increasingly
expected to be a result from alterations in gene and protein
expression. Gene expression is a more static process; how-
ever, protein patterns may be altered faster in close relation-
ship with the appearance of disease, making up an adequate
identiﬁcation of proteome characteristics important. If dif-
ferent etiologies and pathways of cardiac disease progression
can be represented in the form of unequivocal proteomic
patterns, these patterns may help simplify and accelerate
the diagnostics and be used as an appropriate diagnostic
method in daily clinical routine [3–6]. Molecular diﬀerences
extracted out of these patterns may also reveal potential
biomarkers that could be targeted for screening purposes
[7, 8]. A possibility to locate some of these molecules in
circulating blood, where an easy access for high-throughput
assays would be valid, is especially attractive.
The objective of this study is to evaluate selected individ-
ual myocardial samples which are representative for aortic
valve disease (AVD) and coronary heart disease (CHD),
respectively. As presented in our recent study [9], proteomic2 International Journal of Proteomics
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Figure 1: Flowchart for the path of the sample preparation and measurements with 9.4 Tesla FT-ICR MS. The measurement of the samples
with two diﬀerent instrument had the reason that the samples were measured with a classical FT-ICR instrument without external MS/MS
capability. After the diﬀerential mass spectrometric runs followed by the pattern comparison, a quadrupole/hexapole FT-ICR instrument
with external MS/MS capability was available. The fragmentation studies for the protein identiﬁcation were performed with this latter
instrument.
pattern distribution characteristics of myocardial tissue in
AVD and CHD were found to be clearly diﬀerent using
liquid-chromatography Fourier transform ion cyclotron
resonance mass spectrometric (LC-FT-ICR MS) analysis.
Classiﬁcation patterns obtained from the comparison of LC-
FT-ICR MS of digested proteins in the samples could be
used for correctly sorting them in exact categories. The
endogenous proteins were analyzed using a “bottom-up”
proteomic approach that starts by a tryptic digestion of all
the proteins in the samples and then analyzing the digests
throughLCandonlineelectrosprayionizationoftheanalytes
into a quadrupole/hexapole FT-ICR MS. After isolation in
the quadrupole, collision-induced dissociation (CID) of
selected peptides can be performed in the hexapole collision
cell, and using the acquired fragment spectra, proteins
can be identiﬁed by database searches. For comparison
and further validation, selected peptides were also frag-
mented and analyzed using liquid-chromatography-matrix-
assisted laser desorption-ionization time-of-ﬂight/time-of-
ﬂight mass spectrometry (LC-MALDI-TOF/TOF MS). With
the combination of these techniques, the measurement of
peptides from LC-separated samples results in precise mass
information on the ppm-level, in very high resolution and
in high sensitivity that in itself has been successfully used
to explore the protein content of body ﬂuids, for example,
plasma and cerebrospinal ﬂuid (CSF) [10–13]. In addi-
tion, sequence information essential for signiﬁcant protein
identiﬁcation in minute tissue samples, for example, laser-
dissected human spinal cord tissue can be obtained [14].
2.MaterialsandMethods
As a general overview for the method used, a ﬂow chart is
shown in Figure 1 depicting the sample preparation, mass
spectrometric methods and measurements, as well as the
data evaluation.
2.1. Sample Selection and Data. In 20 patients undergoing
cardiac surgery with extracorporeal circulation, right atrial
appendages were subject to removal and discarding for
venouscannulationthatwerecollectedintraoperatively,after
approval by the local ethical committee. The group of
patients consisted of 10 individuals with hemodynamically
signiﬁcant, isolated AVD and 10 with isolated symptomatic
CHD. Patient selection was made in such a way that all
patients with CHD selected for this study were “healthy”
in terms of the AVD and all selected AVD patients were
“healthy” in terms of the coronary disease. The median
age was 62 years (45–81) in the AVD group, and 66
years (37–83) in the CHD group. All antithrombotic agents
were suspended 10–14 days prior to surgery. In all studied
cases, patients stopped taking aspirin one week before the
operation. Cardiac samples (each of them in the range of
1cm 3)wereimmediatelywashedinKrebs-Henseleitsolution
(118mM NaCl, 4.7mM KCl, 1.2mM MgSO4,1 . 2 5 m M
CaCl2,1 . 2m MK H 2PO4,2 5m MN a H C O 3, 11mM glucose)
and ﬁxed on wax plates at room temperature. After separa-
tion from the epicardium, the trabecular tissue was shock-
frozen in liquid nitrogen and stored at −75◦C.International Journal of Proteomics 3
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Figure 2: Non-scaled schematic view of an LC-FT-ICR MS system with a quadrupole mass selector and a hexapole collision cell. In the
electrospray ion source the formed ions are captured after they pass the electrospray capillary in an ion funnel, which increases the sensitivity
ofthesystem by roughly up toan order of magnitude. Ionsare transferredthroughtwo ion funnels intoa hexapole ionguide, where they can
also be trapped. Ions are selected in the quadrupole mass selector and can undergo collision induced dissociation in the hexapole collision
chamber which is at a relatively high pressure. The ICR cell is in the magnetic center of a 9.4T superconducting magnet. The vacuum system,
not shown in the ﬁgure, consists of pumping stages down to the range of 10−10 mbar in the ultra high vacuum chamber of the ICR cell. The
numbers shown are approximate pressures in diﬀerent pumping stages.
2.2. Sample Preparation. Sample selection and preparation
of the tissue specimens have been described in detail in our
earlierstudy[9].Brieﬂy,thetissueswerehomogenizedin8M
urea, 0.4M NH4HCO3 followed by reduction of the disul-
ﬁde bridges, carbamidomethylation of cysteins, and tryptic
digestion according to the manufacture’s protocol (Modiﬁed
Trypsin, sequencing grade, Promega GmbH). The digests
wereSPEextracted(SpecPlusC18 AR,AnsysDiagnosticsInc,
CA),vacuum-centrifugedtodryness,andthenredissolved in
0.1% formic acid before injection into an LC system. Ace-
tonitrile and acetic acid, formic acid and triﬂouro acetic acid
were purchased from Merck (Darmstadt, Germany). Urea,
ammonium carbonate, and iodoacetamide were obtained
from Sigma Chemical Co. (St. Louis, MO, USA) and were
used without further puriﬁcation. Dithiothreitol was pur-
chased from Amersham Biosciences (Uppsala, Sweden). All
used chemicals were of analytical grade. Trypsin, sequence
grade from bovine pancreas (1418475), was obtained from
Roche Diagnostics (Mannheim, Germany). Water was puri-
ﬁed with a Milli-Q puriﬁcation system (Millipore, Bedford,
MA, USA). All fused-silica capillaries were obtained from
Polymicro Technologies (Phoenix, AZ, USA).
2.3. LC/FT-ICR MS/MS for Protein Identiﬁcation. The total
amountofeachdigestedsamplewasdissolvedin250μL0.1%
triﬂuoroacetic acid (TFA), split into 5 vials each of 50μL
sample solution and Speed Vacced to dryness at medium
t e m p e r a t u r e .T h ed r i e ds a m p l eo fo n ev i a lo fe a c hs a m p l e
was dissolved in 50μL 0.1% TFA and diluted 1:10 with
0.1% formic acid. An aliquot of 5μL of the sample solution
was injected on a Nano LC column (see below) for FT-ICR-
NanoLC/MS/MS analysis.
Mass spectra were acquired with an APEX Qe FT-ICR
(Bruker Daltonics Inc., Billerica, MA, USA) equipped with a
9.4Teslasuperconductingmagnet (BrukerBioSpin, Wissem-
bourg, France). A schematic description of the LC-FT-ICR
MS system with a quadrupole mass selector and a hexapole
collisioncellisshowninFigure 2.Sampleswereionizedinan
“Apollo II” electrospray ion source (Bruker Daltonics, Biller-
ica, MA, USA) with ion funnel technology for eﬃcient cap-
ture of the generated ions. Ions were detected in a cylindrical
ion cyclotron resonance cell with segmented trapping plates
(inﬁnity cell) [15]. Nano LC-MS/MS measurements were
performed with a Nano LC system Ultimate 3000 (Dionex,
Sunnyvale, CA, US) ﬁtted with 2 10-port valves. An online-
nanosprayESIsource(BrukerDaltonics,Billerica,MA,USA)
was coupled to the NanoLC system. This ion source was
equipped with an angled oﬀ-axis spraying system, that used
a PicoTip adapter (New Objective, MA, USA) to connect the
tubing of the NanoLC column to a distal-coated fused silica
needle that had a 10μm inner diameter (New Objective, MA,
USA). A spring in the needle holder provided the connection
from the needle to ground potential. The tip of the needle
was placed a few mm in front of the oriﬁce of the glass cap-
illary at an angle of approximately 70◦. The voltage applied
to the metal-coated capillary entrance of the electrospray
source was set to −1500V. The NanoLC column PepMap
C-18 (75μm inner diameter, 15cm length, 5μmp a r t i c l e
size, Dionex, Sunnyvale, CA, USA) was used for compound
separation with a ﬂow of 200nL/min. The peptides were ﬁrst
captured on a C-18 precolumn for desalting of the sample
and eluted from this column to the PepMap column with a
185min gradient for peptide separation of highly complex
sample (solvent A: water with 0.1% formic acid, solvent
B: acetonitrile with 0.1% formic acid, 0min 2% solvent B,
5min 2% solvent B, 175min 40% solvent B, 190min 50%
solvent B, 191min 90% solvent B, 205min 90% solvent B,
206min 2% solvent B, 250min 2% solvent B). After storing4 International Journal of Proteomics
TOF 1 TOF 2
Sample 
target
Gridless DE
MALDI source
Ion source
Timed 
ion selector
Collision
cell
Post-LIFT
metastable
suppressor
Detector
Detector
Source 2
LIFT
Gridless
reﬂector
Analyzer
Laser 
beam
Ion beam
TOF 1 TOF 2
Figure 3: Non-scaled schematic view of a MALDI-TOF/TOF mass spectrometer.
the sample on the precolumn, this column was washed for
5 minutes with 0.1% TFA for desalting using a 30μL/min
ﬂow and than switched to gradient ﬂow. The pressure in the
collision cell (located between the quadrupole ﬁlter and the
ICR analyzer cell) for CID was set by increasing the read-out
pressure of the source ion-gauge to about 4.5 × 10−6 mbar
(approx., a factor of 10 higher than without pressure in
the collision cell). The default parameter setting was used
for collision energy calculation for CID fragmentation. The
FT-ICR mass spectra were acquired with the acquisition
software Apex Control 1.0 (Bruker Daltonics, Billerica, MA,
USA) using data-dependent MS/MS acquisition. The ion
accumulation time was set to 0.5s for the MS scan and 2s for
the MS/MS. The mass range was set to m/z 246 to m/z 2000
for the MS and MS/MS spectra using 512k data points. The
mass spectra were processed with 512k data points and sine
apodization. Further processing of the data including mass
deconvolution and mgf-ﬁle generation for database search
was performed with Data Analysis 3.3 (Bruker Daltonics,
Billerica, MA, USA).
The mass spectra were processed using the protein
analysis software Biotools 3.0 (Bruker Daltonics, Billerica,
MA, USA) for database searches and results interpretation.
The MASCOT search engine (Matrix Science, London, UK)
[16, 17] was used to search the SwissProt database. MOWSE
(molecular weight search) scores, assigned by MASCOT,
were calculated based on the algorithm described by Pappin
et al. [18]. Search criteria for all experiments included
one missed cleavage, taxonomy human, ﬁxed modiﬁcation
carbamidomethyl, and variable modiﬁcations oxidation of
methionine. Mass tolerances for the MS/MS search were set
to 4ppm for the parent mass and 0.01Da for the fragment
masses. In a second search, 2 missed cleavages were allowed,
and in a third search, also unspeciﬁc cleavages were accepted.
Mass spectra were externally calibrated with a siloxane
mixture of the chemical background signals using a two
parameter linear calibration [19].
2.4. LC/MALDI TOF/TOF MS for Protein Identiﬁcation. α-
cyano-hydroxy cinnamic acid (CHCA) and the proﬁling
kit Magnetic Beads based on Weak Cation Exchange
Chromatography (MB-WCX) were obtained from Bruker
Daltonik, Bremen, Germany. HPLC gradient grade and
ammonium citrate, dibasic, ACS grade, were obtained from
Sigma-Aldrich (Steinheim, Germany).
The capillary high-performance liquid chromatography
(HPLC) separations were performed using an Agilent 1100
Cap-LC system equipped with a 15cm × 180μmI . D .
PepMap column with a 3 μmC 18 stationary phase (LC Pack-
ings, Amsterdam, The Netherlands). For all separations
eluent A consisted of 0.1% TFA/water and 2% CH3CN and
eluent B was 0.05% TFA in 100% CH3CN. An isocratic ﬂow
of eluent A, 2μL/min for 5min, was followed by a gradient
from 2% to 40% CH3CN in 90 minutes. All separations were
performed at ambient temperature and the injection volume
was 8μL. After each 15s fractions of 0.5μL were dispensed
onto a spot on the MALDI target.
The MALDI-TOF-MS instrument used was an Ultraﬂex
II TOF/TOF (Bruker Daltonik GmbH, Bremen, Germany)
[20].ItwasequippedwithaSmartBeamlaser[21].Thefocus
diameterwasapproximately60μm.Allspectrawereacquired
using the reﬂectron mode of the instrument (Figure 3)a t
25kV acceleration voltage. While the MS data was recorded
in a fully automated fashion the MS/MS data of peptides
was acquired in a manual operation mode of the instrument.
In order to acquire MS/MS spectra, precursor ions were
accelerated out of ion source (S1) by means of time delayed
extraction. Fragmentation was performed either by laser-
induced or collision-induced dissociation or a combination
of both. The collision cell was located right after S1. Argon
was used as a collision gas. In the ﬁrst ﬁeld free region of
the TOF1, the precursor ions including the already created
related fragment ions are passed straight through an ion
selection unit, while all the rest is deﬂected. The resolution of
this unit is about 750 FWHH (single mass resolution at mass
750Da).Theselectedprecursorionsandtheircorresponding
fragmentionsthenenterasecondionsource(S2).Here,they
are accelerated again, leading to a separation of their mass in
the second ﬁeld free drift region (TOF2). All fragment ions
areseparatedintimeandfocusedinenergyaccordingtotheirInternational Journal of Proteomics 5
m/z (z = 1) by a combination of time-delayed extraction out
ofS2andtimefocusinginthereﬂectronofTOF2.Depending
on their mass, typical fragment ion resolution is in the range
of 2000–5000.
Despite a 90min separation of the peptides in the HPLC
and a spread of fractions onto 384 spots, the acquired MS
spectra were still very complex. On one side, complexity
increased suppression eﬀects during desorption/ionization,
on the other side, selection of individual peptides for MS/MS
often was ambiguous. In order to simplify MS spectra
and avoid mixing of fragments from diﬀerent precursor
ions prior to the LC separation, selected samples were
prefractionated using Magnetic Beads based on Weak Cation
Exchange Chromatography (Proﬁling Kit 100MB-WCX,
Bruker Daltonik GmbH, Bremen, Germany). The freeze-
dried samples were dissolved in 10μL0 . 1 %T F A .A f t e ra
further 1:10 dilution, 5μL was used to bind the peptides
to the beads. 8μL of the supernatant was used in the ﬁrst
run of the LC separation. After washing of the beads with
washing buﬀer, the bound peptides were eluted using 3 ×
3μLo fe l u t i o nb u ﬀer. In order to remove the acetonitrile
from the eluent, the volume was reduced in a speedvac by a
factor of two. The remaining volume of 4μL was then used
for a second run of the LC separation.
The target of choice for the LC-MALDI approach was
a prespotted Anchor Chip target (Bruker Daltonik GmbH,
Bremen, Germany). Within a 90min LC run, all 384 sample
spots on the target were prepared. After evaporation of the
solvent, the target was washed by dipping it for a few seconds
into a solution of 10mM ammonium citrate/0.1% TFA.
The sample plate was then introduced into the Ultraﬂex
II MALDI-TOF mass spectrometer, and mass spectra were
recorded from each prepared sample spot. The calibration
used was an external near-neighbor calibration by means
of additional 96 prespotted calibration spots. The sample
used for calibration was a mixture of peptides covering the
mass range from 700Da–3500Da already prepared onto the
disposable target. The acquisition process was controlled by
the WARP-LC software (Bruker Daltonik GmbH, Bremen,
Germany) and a compound list was created. From these
peptide masses, scored according to their signal-to-noise
and the complexity of the MS spectrum, the candidates
of possible biomarkers were selected manually and their
MS/MS spectrum was recorded.
ThespectrawereprocessedbymeansofFlexAnalysisand
the peak lists were sent to BioTools for the database search
using Mascot (Matrix Science, London, UK, [17]). The
following search parameters were chosen for the database
search. Taxonomy: human; database: SwissProt, variable
modiﬁcation:carbamidomethylation(C)andoxidation(M):
MS/MS tolerance: 0.5Da, Partials: 1. In a second search, 2
missed cleavages were allowed, and in a third search also
unspeciﬁc cleavages were accepted.
2.5. Pattern Recognition and Extraction of Classiﬁcation
Features. The pattern recognition and classiﬁcation strategy
have been described in detail by Ramstr¨ om et al. [10]a n d
in Baykut et al. [9]. Brieﬂy, a numerical code was developed
for the analysis. The ﬁrst part of the code normalizes the
spectrogram intensity, removes the noise, and calibrates the
individual HPLC/FT-ICR mass chromatograms in time to
a common “table” sample. The second part of the code
concerns the calibrated sample classiﬁcation and extraction
of the classiﬁcation features. In case of a binary classiﬁcation,
the features are represented by those pattern peaks, which
are more abundant in the majority of the samples of one
class. These peaks are deﬁned as the characteristic peaks.
Thus, two lists of characteristic peaks were generated for
each classiﬁcation. To extract the classiﬁcation features, the
selection of best individual features was applied and the
“nearest mean classiﬁer” was used for the classiﬁcation of
test samples and the sample projection onto classiﬁcation
patterns.
3. Results
Examplesoftwo-dimensionaldataobtainedfromHPLC-FT-
ICR mass spectrometry are shown in Figure 4 for an aortic
(a) and a coronary (b) sample.
3.1. Comparison and Classiﬁcation. As described in detail in
our recent publication [9], the classiﬁcation using 240 char-
acteristicpeaksintheCHDgroupand90characteristicpeaks
in the AVD group analyzed using LC-FT-ICR MS (Figure 2)
resulted in a clear diﬀerence in distribution patterns. In
Figure 5, the symbols represent both cardiac disorders accu-
mulated on either side of the diagonal line with increased
distance from the diagonal related to the speciﬁcation for
the particular type of disease. Above the diagonal, samples
from myocardial tissue with CHD and below the diagonal
samples from myocardial tissue with AVD are located. Each
ﬁlled symbol represents an individual supervised classiﬁed
training sample while each open symbol shows an individual
unsupervised classiﬁed test sample. The algorithm led to
two ambiguous classiﬁcations of the unknown test samples.
Whenthemasschromatogramsfortheseambiguoussamples
were manually inspected, large gaps in the total ion chro-
matograms due to unstable electrospray and sudden changes
in elution rates could be observed, resulting in diﬃculties for
the algorithm to correctly calibrate and align the datasets.
There were intense and stable representative peaks found in
both classes. Having a clear diﬀerence in proteomic pattern
between both myocardial disorders, no interference between
aortic and coronary samples was registered, even if the dis-
tribution of open spots on either sides of the diagonal (unsu-
pervised classiﬁed test samples) displayed a closer distance to
the diagonal. The AVD samples showed a closer accumula-
tion pattern of the spots, indicating a more speciﬁc classiﬁ-
cation of the proteins compared to the coronary samples.
3.2.ProteinIdentiﬁcationResults. Usingthedigestedproteins
from chosen samples from patients with CHD as well as with
AVD, selected classiﬁer masses were fragmented by collision-
induceddissociationinthehexapolecollisionchamberofthe
FT-ICR system. Fragmentation spectra of these peptides are
used for the identiﬁcation of the proteins by database search6 International Journal of Proteomics
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Figure 4: Examples of data (m/z versus number of accumulated scans (corresponds to LC retention time), 10 seconds each) obtained from
HPLC-FT-ICR mass spectrometry of aortic (a) and coronary (b) samples. The light spots in the diagrams correspond to individual mass
spectral peaks. In the original diagrams the peak intensities are color coded for easy recognition. (Figure modiﬁed from reference [9] with
kind permission from the publisher).
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Figure 5: Pattern for the classiﬁcation of coronary (circular
symbols) versus AVD disease (square symbols) samples. Each
point represent an individual sample where ﬁlled symbols (• and
) represent supervised classiﬁed training samples while open
symbols (  and ) represent unsupervised classiﬁed test samples.
All samples with exception of two were unambiguously correctly
classiﬁed.(Figuremodiﬁedfromreference[9]withkindpermission
from the publisher).
(MASCOT search, [17]). Tables 1(a) and 1(b) show the
results obtained from HPLC-FT-ICR MS/MS experiments
for CHD and AVD samples, respectively. In samples from
patients with CHD, four major proteins were identiﬁed
from classiﬁers with a relatively high MASCOT score these
are myosin heavy chain alpha isoform, myosin heavy chain
beta isoform, adenylate kinase, and troponin T (Table 1(a)).
Aortic smooth muscle actin was also identiﬁed, with a
relatively low MASCOT score, however, still in the useful
range when MS/MS of single masses are performed. A larger
number of proteins were identiﬁed from classiﬁers in sam-
ples from patients with AVD: these were mainly troponin T,
desmin, myoglobin, alpha cardiac actin, collagen alpha chain
precursor, lumican precursor, tropomyosin I alpha chain,
alphacrystallinbetachain,cytochromeCoxydase,ADP/ATP
translocase, and serum albumin precursor (Table 1(b)).
Tables 2(a) and 2(b) reveal the protein identiﬁca-
tion results from database searches with HPLC-MALDI-
TOF/TOF spectra of samples from CHD and AVD groups,
respectively. In samples from patients with CHD, seven main
proteins are found: these were myosin heavy chain beta
isoform, alpha crystallin B chain, collagen, elongation factor,
hypothetical protein DKFZp686P07163, adenylate kinase,
and myosin light chain 2a (Table 2(a)). Like in the FT-ICR
results, samples from patients with AVD revealed a larger
number of proteins: these were desmin, alpha cardiac actin,
myosin heavy chain alpha isoform, myosin heavy chain beta
isoform, myosin light chain 2a, ADP/ATP carrier protein,
cytochrome C oxydase, alpha-1 (III) collagen,alpha integrin,
and an unnamed protein product (Table 2(b)).
ExamplesfromMS/MSresultsacquiredwithFT-ICRand
M A L D I - T O Fm a s ss p e c t r o m e t r ya sc o m p a r a t i v ec a s e sa r e
shown in Figures 6 to 9. Figure 6(a) shows the Electrospray
Ionisation-FT-ICR MS/MS spectrum obtained from one
of the AVD samples leading to the identiﬁcation of the
p r o t e i nD e s m i n( D E S MHUMAN), while Figure 6(b) shows
theMS/MSspectrumfromthissamplebyMALDI-TOF/TOF
mass spectrometry. In both cases, suﬃcient sequence infor-
mation is obtained to identify Human Desmin. In the
ESI-FT-ICR MS/MS spectrum, the intensities of the y
fragment peaks are higher than the b fragments. Yet, the
sequence information from both y and b fragments were
usable. Similarly, Figures 7(a) and 7(b) show the ESI-
FT-ICR MS/MS spectra, and MALDI-TOF/TOF spectra,
respectively, obtained from a CHD sample. Adenylate kinase
(KAD1 HUMAN) could be identiﬁed from any of these two12 International Journal of Proteomics
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Figure 6: MS/MS spectra of the classiﬁer peptide FLEQQNAALAAEVNR from the sample of an aortic patient. The protein is identiﬁed as
Desmin upon database search. Spectrum (a) is obtained by LC-ESI-FTMS/MS, spectrum (b) by LC-MALDI-TOF/TOF.
spectra by database search. Here, the ESI-FT-ICR MS/MS
spectrum mainly shows y fragments, while in the MALDI-
TOF/TOF spectrum y, b, and a fragments are visible. Figures
8(a) and 8(b) show the ESI-FT-ICR MS/MS and MALDI-
TOF/TOF mass spectra from an AVD sample, respectively,
from any of which the protein myosin heavy chain beta iso-
form MY7 HUMAN could be identiﬁed due to the sequence
information. Again here, the ESI-FT-ICR MS/MS spectrum
shows mainly the y fragments while MALDI-TOF/TOF
spectrum shows b, y, and a fragmentation. Figure 9 is the
identiﬁcationofbetaactinACTB HUMANwithESI-FT-ICR
MS/MS (a) and MALDI TOF/TOF (b) again from an AVD
sample.
4. Discussion
In this work, the sample collection was made in such a way
that all patients with CHD selected for this study were
free from AVD, and all selected AVD patients were free
from CHD. All comparisons presented in this work can,
therefore, virtually be considered as to be “diseased” versus
“healthy” case against each other. Diﬀerences in the mass
chromatograms are determined as classiﬁer masses. Thus,
proteins identiﬁed from classiﬁers by this diﬀerential mass
spectrometry method are biomarkers in the corresponding
disease case (Figure 10).
Some of the identiﬁed proteins appear both in the list
of CHD samples as well as in the list of the AVD samples.
As an example, myosin heavy chain alpha and beta isoforms
have been found both in CHD and AVD cases (Tables 1
and 2). However, classiﬁer peptides leading to apparently
the same protein by database search were diﬀerent in CHD
samples than in AVD samples. In samples from CHD group,
myosin heavy chain alpha isoform was found by database
search from MS/MS and identiﬁcation of the two classiﬁer
peptides (Table 1(a)). In samples from AVD group, entirelyInternational Journal of Proteomics 13
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Figure 7: MS/MS spectra of the classiﬁer peptide GQLVPLETVLDMLR from the sample of an aortic patient. The protein is identiﬁed as
Adenylate Kinase upon database search. Spectrum (a) is obtained by LC-ESI-FTMS/MS, spectrum (b) by LC-MALDI-TOF/TOF.
diﬀerent classiﬁer peptides led to myosin heavy chain alpha
by database search (Table 1(b)).These are displayed in a sim-
pliﬁed table (Table 3). A targeted analysis of these potential
biomarker peptides could thus result in a simpliﬁed diagnos-
tic assay for diﬀerent etiologies in cardiovascular diseases.
The explanation of this observation is suggested as follows.
The approach in the present study is the analysis of a peptide
mixture resulting from a tryptic digestion of the initial pro-
teinmixture.AcomparisonoftheLC-MSdataleadstoclassi-
ﬁermassesforsampleswithAVDindicatingthatthesepartic-
ular masses (peptides) are here signiﬁcantly more abundant
thaninthesampleswithCHD,andviceversa.However,since
thesepeptidesaretheresultofatrypticdigestionoftheinitial
proteins, any factor inﬂuencing the digestion by trypsin
can very well suppress the appearance of some peptides in
the digest. If, for example, in CHD samples, some of the
tryptic cleavages are suppressed, the comparison will show
a higher abundance of these particular digestion products
in the aortic samples that they become classiﬁers for AVD.
Similarly, if certain tryptic cleavages are suppressed in sam-
ples from AVD patients, the resulting peptides appear more
abundant in samples from CHD group, and the comparison
will indicate them as classiﬁers for CHD samples. One of the
major factors altering the digestion speciﬁcity of trypsin is a
posttranslational modiﬁcation near the cleavage site of the
protein. Thus, a tryptic cleavage at this particular site can
sometimes be not successful. Heavy groups like large glycans
may hinder a cleavage, or even if a cleavage occurs, digested
peptidewiththemodiﬁcationistooheavyandmaybeoﬀthe
detected mass range. It is known that glycosylation can even
completely block the tryptic digestion of a protein [22].
Based on the thoughts above, a possible explanation
for the diﬀerent classiﬁer peptides in CHD and AVDs
leading to the same myosin may be diﬀerences in tryptic
digestion patterns caused by posttranslational modiﬁcations
at diﬀerent positions. An investigation of the correlation
to these diﬀerences is the topic of our ongoing work. For
this particular study, fragmentations by electron capture14 International Journal of Proteomics
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Figure 8: MS/MS spectra of the classiﬁer peptide GSSFQTVSALHR from the sample of an aortic patient. The protein is identiﬁed as Myosin
Heavy Chain Beta Isoform upon database search. Spectrum (a) is obtained by LC-ESI-FTMS/MS, spectrum (b) by LC-MALDI-TOF/TOF.
dissociation (ECD) or electron transfer dissociation (ETD)
are more suitable than collision-induced dissociation (CID),
since ECD and ETD protect posttranslational modiﬁcations
while breaking the peptide backbone bonds.
Another possible reason for altered digestion speciﬁcity
of trypsin could be the folding geometry. If the protein is not
completelyunfoldedduringthedigestionprocess,thetryptic
cleavage at particular sites can be sterically hindered. This
would then lead to missed cleavages.
A number of proteins in ESI-FT-ICR MS/MS were
also identiﬁed with the method MALDI-TOF/TOF mass
spectrometry with the same peptide sequences. In samples
from the CHD group, commonly identiﬁed proteins were
adenylate kinase, myosin heavy chain beta isoform. In sam-
ples from the AVD group, the proteins commonly identiﬁed
in FT-ICR MS/MS and TOF/TOFwere desmin, alpha cardiac
actin,myosinheavychainalphaisoform,myosinheavychain
beta isoform, and ADP/ATP translocase [23].
As described previously, FT-ICR and MALDI-TOF mass
spectrometry used diﬀerent methods of ionization. For the
FT-ICR MS, ions were separated by liquid-chromatography
andonlineionizedbyelectrosprayionizationandtransferred
into mass spectrometer—either directly or after collision-
induced dissociation—for detection. The MALDI-TOF mass
spectrometric method uses samples in deposited solid phase.
Thus, the components in the samples were LC-separated
ﬁrst and fractions were deposited on a MALDI sample plate
precoated with a alpha-cyano-4-hydroxy cinnamic acid as a
matrix (Pre Spotted Anchor Chip target. Bruker Daltonik,
Bremen, Germany). This plate was inserted into the ion
source of the TOF mass spectrometer, irradiated with the
laser beam, and the ions were generated by matrix assisted
laser desorption/ionization and detected. These ions are
in general singly charged. Although compounds in both
MALDI and electrospray ionization become mildly ionized,
due to the diﬀerent ionization techniques in MALDI-TOFInternational Journal of Proteomics 15
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Figure 9: MS/MS spectra of the classiﬁer peptide IWHHTFYNELR from the sample of an aortic patient. The protein is identiﬁed as Beta
Actin upon database search. Spectrum (a) is obtained by LC-ESI-FTMS/MS, spectrum (b) by LC-MALDI-TOF/TOF.
Figure 10: Proteomic proﬁles of myocardial tissue in two diﬀerent etiologies of heart failure were investigated using right atrial appendages
samples representative for the aortic valve disease and coronary heart disease using a quadrupole/hexapole FT-ICR MS that allowed collision
induced dissociation (CID) of selected classiﬁer masses. For comparison and further validation, classiﬁer masses were also fragmented and
analyzed using HPLC/Matrix assisted laser desorption ionization (MALDI) time-of-ﬂight/time-of-ﬂight (TOF/TOF) mass spectrometry.16 International Journal of Proteomics
Table 3: Classiﬁer peptides in aortic and coronary diseases identifying myosin heavy chain alpha and beta isoforms as potential biomarkers.
Classiﬁer peptides
Identiﬁed protein CHD disease AVD disease
Myosin heavy chain alpha isoform
KLAEKDEEMEQAK, RKLEGDLK,
NLQEEISDLTEQLGEGGKNVHELEKVR
AQLEFNQIK,
GSSFQTVSALHR,
GKLSYTQQMEDLKR
Myosin heavy chain beta isoform KLAEKDEEMEQAK
RKLEGDLK,
AQLEFNQIK,
GSSFQTVSALHR
and FT-ICR instruments, and to the non-online method in
the LC-MALDI-TOF, some of the ions may have diﬀerent
abundances than in the on-line system. Thus, some of
the FT-ICR MS/MS or MALDI-TOF/TOF dissociations of
classiﬁers could not be performed as the abundance in
the corresponding system was low. One of the examples is
the alpha crystallin B chain [24–27] in the CHD samples
which is intensively found in the MALDI-TOF spectra,
fragmented (TOF/TOF), detected, and identiﬁed, which was
not suﬃciently abundant in the experiments with the FT-
ICR MS. Thus, no results regarding detection of alpha
crystallin B chain have been displayed in the CHD samples
by FT-ICR MS.
As an overview, the bottom-up proteomic approach
was applied to proteins in human cardiac muscle tissue
samples from two groups of patients in this study. The
selection of patients enabled the examination of two clearly
separated case etiologies. Proteins in the tissue samples were
digested by trypsin, and the digest containing a mixture
of peptides was analyzed by mass spectrometry after liquid
chromatographic separation. The use of high-resolution
mass spectrometry (in this case FT-ICR MS) allowed to
resolve and display the mass spectrometric peaks in this
complex picture of the LC-MS results and to compare both
separate disease forms. By comparison of LC-MS diagrams,
the classiﬁer masses could be clearly identiﬁed. These were
selected in the subsequent experiments and fragmented
(LC-FT-ICR MS/MS), in order to identify the proteins
which had generated the classiﬁer masses. The comparison
clearly separated both disease forms while the analysis and
identiﬁcation of the proteins which led to the classiﬁers
helped to study the biomarkers related to CHD and AVD.
An additional work for comparing LC-MALDI-TOF mass
spectrometry and LC-MALDI TOF/TOF for the MS/MS
fragmentation has also be performed.
Theuniquepatientselectioninthisstudy,combinedwith
the bottom-up proteomic approach using liquid chromatog-
raphy and high resolution mass spectrometry, seems to be
highly eﬃcient in determination of the diﬀerences between
selected disease groups. The diﬀerential high-resolution mass
spectrometry performed subsequently to characterize the
related proteins did require the MS/MS of the classiﬁer
masses only.
This study of the heart muscle tissue samples helped
establish a ﬁrst picture of the proteomic appearance of two
virtually independent etiologies of heart disease. As our
main target is to diagnose cardiac disease less invasively
and directly, we are currently investigating blood plasma
samples from CHD and AVD patients in order to identify the
diﬀerences with the same technique using diﬀerential high-
resolution mass spectrometry.
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